Economists have long debated whether granting people financial incentives to donate kidneys is the best way to handle this massive supply-demand imbalance. Financial incentives appear to be a powerful approach to enhancing public health, according to rising data from studies in other fields of medicine.
"There is a significant disparity between
deceased contribution and existing demand." "Deceased donation can
never replace this need," says Dorry Segev, an associate professor of
surgery at Johns Hopkins University School of Medicine. He goes on to say that
individuals are living longer lives and are becoming more prone to conditions
like high blood pressure, which make kidney donation unfeasible. "So you
have to try to recruit living donors to match the existing need."
A Kidney
Transplant Market is dependent on a variety of scenarios
and conditions, such as renal failure caused by a variety of factors (kidney
trauma, severe dehydration). Because a human can live for years with one
kidney, it is not a popular treatment in many nations. Furthermore, in
developing nations, the cost of a kidney transplant is too expensive.
The early hurdles of medical and surgical
complications associated with kidney transplantation have already been
overcome, and there is a progressive shift toward more transplant facilities
offering laparoscopic donor nephrectomy, with a few also offering robotic Kidney Transplant Market.
However, there are currently no long-term studies in India looking at the
health of kidney donors. The increased prevalence of lifestyle disorders such
as diabetes and hypertension necessitates long-term monitoring of kidney donors
in India.
Increasing the use of living donors is currently the
greatest answer to the organ scarcity problem. The clinical problems posed by
the first living donor Kidney
Transplant Market, such as donor risk, informed consent,
donor protection, and organ quality, have mostly been addressed. We firmly
advocate for greater use of living donation and advocate that living
donation, rather than a deceased donation, be the first choice for kidney transplantation.
Important Players
Sanofi, Pfizer, Inc., Novartis AG, B. Braun Melsungen
AG, Fresenius Medical Care, Medtronic, Preservation Solution Inc., TransMedics,
Inc., Organ Recovery Systems, and Transonic Systems Inc. are among the major
participants in the global kidney transplant market.
0 Comments